Sinco Pharmaceuticals Holdings Limited

Equities

6833

KYG8154Y1052

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 am EDT 5-day change 1st Jan Change
0.255 HKD +2.00% Intraday chart for Sinco Pharmaceuticals Holdings Limited +4.08% +6.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments MT
Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director CI
Sinco Pharmaceuticals Warns of Lower 2023 Profit MT
Sinco Pharmaceuticals Holdings Limited Provides Consolidated Earning Guidance for the Year Ended 31 December 2023 CI
Sinco Pharmaceuticals Holdings Limited(SEHK:6833) dropped from S&P Global BMI Index CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sinco Pharmaceuticals Warns of 68% Drop in H1 Profit MT
Sinco Pharmaceuticals Holdings Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 CI
Sinco Pharma Taps Moore Advisory Services for Internal Control Review MT
Sinco Pharmaceuticals Co-CEO Resigns; Shares Slip 3% MT
Sinco Pharmaceuticals Holdings Limited Announces Final Dividend for the Year Ended 31 December 2022, Payable on June 15, 2023 CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sinco Pharmaceuticals Holdings Limited Announces Chief Executive Officer Changes CI
Sinco Pharmaceuticals Holdings Limited Appoints Lei Shifeng as Executive Director, with Effect from 29 March 2023 CI
Sinco Pharmaceuticals Expects 50% Drop in 2022 Profit; Shares Slip 4% MT
Sinco Pharmaceuticals Holdings Limited Provides Group Earnings Guidance for the Year Ended 31 December 2022 CI
Sinco Pharmaceuticals Holdings Limited completed the acquisition of Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun. CI
Sinco Pharmaceuticals Searching for New Auditor Following EY's Resignation MT
Sinco Pharmaceuticals Unit, Beijing Nuokangda Sign Agreements for Facial Needle Development MT
Sinco Pharmaceuticals Holdings Limited Enters into the Secret Needle Technological Development Agreements with Beijing Nuokangda CI
Sinco Pharmaceuticals Holdings Limited(SEHK:6833) added to S&P Global BMI Index CI
Sinco Pharmaceuticals' H1 Profit Down on Higher Selling Costs MT
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Sinco Pharmaceuticals Holdings Limited
More charts
Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.
More about the company